Previous 10 | Next 10 |
Precigen (PGEN) announces that the US FDA has granted orphan drug designation ((ODD)) for PRGN-2012, a first-in-class, investigational off-the-shelf ((OTS)) AdenoVerse immunotherapy for recurrent respiratory papillomatosis ((RRP)), a rare, difficult-to-treat and sometimes fatal...
Precigen Receives FDA Orphan Drug Designation for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP) - RRP is a rare, difficult-to-treat and sometimes fatal neoplastic disease of the upper and lower respiratory tracts caused by...
Precigen, Inc. (PGEN) Q4 2020 Earnings Conference Call Mar 01, 2020, 04:30 PM ET Company Participants Steven Harasym - Head, IR Helen Sabzevari - President & CEO Tom Samuelson - Head, Financial Strategy Conference Call Participants Jason Butler - JMP Securities Chuck Whitesell - Wells Far...
Image source: The Motley Fool. Precigen, Inc. (NASDAQ: PGEN) Q4 2020 Earnings Call Mar 1, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Precigen, Inc. (PGEN) Q4 2020 Earnings Call Transcript
Precigen (PGEN): Q4 GAAP EPS of -$0.23 misses by $0.07.Revenue of $19.33M (+13.7% Y/Y) misses by $1.87M.Press Release For further details see: Precigen EPS misses by $0.07, misses on revenue
Precigen Reports Fourth Quarter and Full Year 2020 Financial Results - Company successfully accomplished anticipated 2020 clinical milestones despite challenges due to the ongoing pandemic - - Strengthened balance sheet with successful public offering while streamlining oper...
Precigen to Announce Fourth Quarter and Full Year 2020 Financial Results on March 1st - Management will also present at the H.C. Wainwright Virtual Global Life Sciences Conference; webcast available March 9th - PR Newswire GERMANTOWN, Md. , Feb. 22, 2021 /PRN...
Miller Value Partners is a value investor. It values businesses, and not just stocks, and invests in them for the long term. Miller Opportunity Equity ended the year on a strong note, notching a 35.4% (net of fees) gain in the quarter versus the S&P 500’s 12.15%. This broug...
Vor Biopharma (VOR) has priced its initial public offering of ~9.83M shares at $18/share, for gross proceeds of ~$176.9M.The company originally planned to offer 8.8M shares at a price range of $16-$18.Underwriters' over-allotment is an additional 1,474,202 shares. Shares to kick-off trading t...
Precigen to Participate in Guggenheim Healthcare Talks Oncology Day PR Newswire GERMANTOWN, Md. , Feb. 4, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to ...
News, Short Squeeze, Breakout and More Instantly...
2024-06-03 14:30:04 ET Stifel Nicolaus analyst issues MARKET OUTPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Market Outperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst co...
2024-06-03 14:30:03 ET JMP Securities analyst issues UNDERPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Underperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst consensus : B...
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response PR Newswire – Phase 1/2 pivotal study met the primary safety and efficacy endpoints ...